# CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

> **NCT05270772** · PHASE1 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 9 (estimated)

## Conditions studied

- CD19+ Relapse/Refractory B-ALL

## Interventions

- **BIOLOGICAL:** CAR-T-19 Cells

## Key facts

- **NCT ID:** NCT05270772
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-25
- **Primary completion:** 2022-07-15
- **Final completion:** 2024-09-16
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270772, "CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05270772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*